StockData
Co-Diagnostics, Inc. logo

Co-Diagnostics, Inc. (CODX) stock

CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$0.22−0.03 (-13.03%)

Close on Nov 16, 2026Market cap $1.41MP/E –Yield –

Co-Diagnostics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Co-Diagnostics's free cash flow for the twelve months ending Jun 30, 2026 was -$27.47M. For fiscal 2025 it was -$29.84M. The highest annual figure on record is $40.41M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.84M–
FY2024Dec 31, 2024-$29.90M–
FY2023Dec 31, 2023-$23.45M-556.1%
FY2022Dec 31, 2022$5.14M-87.3%
FY2021Dec 31, 2021$40.41M+47.5%
FY2020Dec 31, 2020$27.39M–
FY2019Dec 31, 2019-$5.64M–
FY2018Dec 31, 2018-$4.12M–
FY2017Dec 31, 2017-$3.34M–
FY2016Dec 31, 2016-$1.32M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.17M–
Q1 FY2026Mar 31, 2026-$7.99M–
Q4 FY2025Dec 31, 2025-$6.33M–
Q3 FY2025Sep 30, 2025-$5.98M–
Q2 FY2025Jun 30, 2025-$8.69M–
Q1 FY2025Mar 31, 2025-$8.84M–
Q4 FY2024Dec 31, 2024-$8.30M–
Q3 FY2024Sep 30, 2024-$7.40M–
Q2 FY2024Jun 30, 2024-$5.30M–
Q1 FY2024Mar 31, 2024-$8.89M–
Q4 FY2023Dec 31, 2023-$5.24M–
Q3 FY2023Sep 30, 2023-$6.00M-775.7%
Q2 FY2023Jun 30, 2023-$6.10M-632.3%
Q1 FY2023Mar 31, 2023-$6.10M-182.3%
Q4 FY2022Dec 31, 2022-$4.30M-190.5%
Q3 FY2022Sep 30, 2022$888.27K-92.2%
Q2 FY2022Jun 30, 2022$1.15M-90.6%
Q1 FY2022Mar 31, 2022$7.41M-38.9%
Q4 FY2021Dec 31, 2021$4.76M-75.6%
Q3 FY2021Sep 30, 2021$11.34M+34.2%
Q2 FY2021Jun 30, 2021$12.18M+1280.9%
Q1 FY2021Mar 31, 2021$12.13M–
Q4 FY2020Dec 31, 2020$19.49M–
Q3 FY2020Sep 30, 2020$8.46M–
Q2 FY2020Jun 30, 2020$882.15K–
Q1 FY2020Mar 31, 2020-$1.44M–
Q4 FY2019Dec 31, 2019-$1.65M–
Q3 FY2019Sep 30, 2019-$1.24M–
Q4 FY2018Dec 31, 2018-$999.47K–
Q3 FY2018Sep 30, 2018-$1.18M–
Q2 FY2018Jun 30, 2018-$967.98K–
Q1 FY2018Mar 31, 2018-$978.21K–
Q4 FY2017Dec 31, 2017-$1.03M–
Q3 FY2017Sep 30, 2017-$1.55M–
Q2 FY2017Jun 30, 2017-$294.43K–
Q1 FY2017Mar 31, 2017-$460.78K–
Q4 FY2016Dec 31, 2016-$560.64K–
Q3 FY2016Sep 30, 2016-$298.06K–

More Co-Diagnostics figures

See a number that looks wrong?